Gilead Sciences, Inc. (GILD) vs Kymera Therapeutics, Inc. (KYMR)
The same free fields, in the same order, for both companies, so a figure on one line can be read straight across.
This page states measurements and nothing else. It does not rank the two companies, name one of them, or draw a conclusion from the figures.
Data as of Oct 27, 2026, for both companies.
The figures, field by field
A dash means the snapshot carries no figure for that company on that line. A line is dropped only when neither company has it, so a dash beside a figure is a fact about coverage, not about either company.
| GILD | KYMR | |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Biotechnology |
| Size band | LARGE | MID |
| Listing | Nasdaq GS | Nasdaq GM |
| Country | United States | United States |
| Theme | pharmaceuticals-large-cap | rare-disease |
| Price and returns | ||
| Last close | $158.69 | $114.84 |
| Return · 1 week | +3.67% | +6.26% |
| Return · 1 month | +4.26% | +2.54% |
| Return · 3 months | +18.14% | +8.18% |
| Return · year to date | +31.24% | +57.83% |
| Return · 1 year | +33.35% | +88.73% |
| Distance from the 52-week highThe last close measured against the highest close of the past 52 weeks. | −1.13% | −11.70% |
| 52-week high | $160.51 | $130.05 |
| 52-week low | $114.02 | $55.26 |
| Size and turnover | ||
| Market value · USDConverted to US dollars, so two companies listed in different currencies sit under one heading. | $196.77B | $9.21B |
| Turnover · median day, USDThe median value traded in a session over the past 50 sessions. | $847.37M | $80.55M |
| Employees | 17,000 | 273 |
| Valuation | ||
| Price to earnings · trailing | n/a (negative earnings) | n/a (negative earnings) |
| Price to earnings · forward | 15.64× | n/a (negative forward earnings) |
| Price to sales | 6.35× | 89.01× |
| Price to book | 16.37× | 6.17× |
| Enterprise value to EBITDA | 14.71× | n/a (negative EBITDA) |
| Enterprise value to revenue | 7.05× | 79.97× |
| PEG ratio | 2.31 | — |
| Earnings per share · trailing | -2.65 | -3.25 |
| Profitability | ||
| Gross margin | 79.59% | — |
| Operating margin | 33.68% | −116.32% |
| Profit margin | −10.64% | −285.33% |
| Return on equity | −20.68% | −24.15% |
| Return on assets | 14.09% | −15.59% |
| Growth | ||
| Revenue growth | +10.20% | +466.40% |
| Balance sheet and payout | ||
| Debt / equity (%) | 223.47 | 5.21 |
| Current ratio | 1.27 | 10.34 |
| Dividend yield | 2.10% | 0.00% |
| Payout ratio | 43.46% | 0.00% |
| Trend and volatility | ||
| RSI · 14 | 61.88 | 55.71 |
| ADX · 14 | 22.95 | 11.90 |
| 50-day average | $149.25 | $114.96 |
| 200-day average | $139.06 | $95.46 |
| Average true range · share of priceAverage true range over 14 sessions, stated as a share of the last close, so it can be read across two share prices. | 2.60% | 4.13% |
The full GILD analysis
Everything this table leaves out for Gilead Sciences, Inc.: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the GILD argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full GILD analysisThe full KYMR analysis
Everything this table leaves out for Kymera Therapeutics, Inc.: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the KYMR argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full KYMR analysis